Skip to content

Study · Randomized controlled trial · n = 34 · 1996

5 results

Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group.

The source lists no authors.

Fertility and sterility1 Dec 1996Cited by 31 (Europe PMC)

PMID8941054 (opens in a new tab)DOI10.1016/s0015-0282(16)58682-8 (opens in a new tab)PepBankPUB-08941054
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, pain recurred in 9 of 17 leuprolide recipients (52.9%) versus 2 of 17 gestrinone recipients (11.8%).

    In plain wordsIn women with endometriosis, moderate or severe pain recurred more often after leuprolide than after gestrinone.

    Peptide
    Leuprolide
    Outcome
    IncreaseModerate or severe pain recurrence
    Study

    n = 34

    Comparator
    Gestrinone
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Moderate or severe pain recurrence
    52.9%
    leuprolide acetate, 9 of 17
    Moderate or severe pain recurrence
    11.8%
    gestrinone, 2 of 17
    Odds ratio
    0.12 ratio
    Gestrinone versus leuprolide
    Confidence interval
    0.02 to 0.69 95% CI
    Gestrinone versus leuprolide

    Source sentences

    Summary
    Moderate or severe pain symptoms recurrence on both pain scales was observed in 2 of 17 (11.8%) patients given gestrinone compared with 9 of 17 (52.9%) of those given LA (odds ratio, 0.12; 95% confidence interval, 0.02 to 0.69).
    3 context sentences
    Summary · context
    Multicenter, double-blind, double-dummy, randomized clinical trial.
    Summary · context
    Fifty-five women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with oral gestrinone (n = 27) or IM depot LA (n = 28) followed by 6-month follow-up.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, dysmenorrhea, deep dyspareunia, and nonmenstrual pain improved significantly with both leuprolide and gestrinone.

    In plain wordsIn women with endometriosis, menstrual pain, pain during intercourse, and nonmenstrual pain improved from baseline with both leuprolide and gestrinone.

    Peptide
    Leuprolide
    Outcome
    DecreaseDysmenorrhea, deep dyspareunia, and nonmenstrual pain
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant improvements were observed in all three symptoms considered in both treatment arms.
    4 context sentences
    Summary · context
    Variations in severity of dysmenorrhea, deep dyspareunia, and nonmenstrual pain as shown by a visual analog scale and a verbal rating scale, modifications in bone mineral content as shown by dual-roentgenogram absorptiometry, and variations in serum cholesterol subfractions and lipoprotein(a) concentrations.
    Summary · context
    Multicenter, double-blind, double-dummy, randomized clinical trial.
    Summary · context
    Fifty-five women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with oral gestrinone (n = 27) or IM depot LA (n = 28) followed by 6-month follow-up.
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, lumbar bone mineral density decreased by 3% during leuprolide treatment.

    In plain wordsIn women with endometriosis, lumbar bone mineral density decreased by 3% from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseLumbar bone mineral density
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Decrease in lumbar bone mineral density
    3%
    leuprolide acetate group

    Source sentences

    Summary
    Lumbar bone mineral density increased slightly in the gestrinone group but decreased by 3% in the LA one.
    3 context sentences
    Summary · context
    Multicenter, double-blind, double-dummy, randomized clinical trial.
    Summary · context
    Fifty-five women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with oral gestrinone (n = 27) or IM depot LA (n = 28) followed by 6-month follow-up.
  4. 04HumanNon-randomized trialSafety outcome

    In women with endometriosis, HDL cholesterol did not vary during leuprolide treatment.

    In plain wordsIn women with endometriosis, HDL cholesterol did not change from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeHDL cholesterol
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    High-density-lipoprotein cholesterol fell by 25% and lipoprotein(a) decreased by approximately 40% in the gestrinone-treated women but did not vary in those receiving LA.
    3 context sentences
    Summary · context
    Multicenter, double-blind, double-dummy, randomized clinical trial.
    Summary · context
    Fifty-five women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with oral gestrinone (n = 27) or IM depot LA (n = 28) followed by 6-month follow-up.
  5. 05HumanNon-randomized trialSafety outcome

    In women with endometriosis, lipoprotein(a) did not vary during leuprolide treatment.

    In plain wordsIn women with endometriosis, lipoprotein(a) did not change from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeLipoprotein(a)
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    High-density-lipoprotein cholesterol fell by 25% and lipoprotein(a) decreased by approximately 40% in the gestrinone-treated women but did not vary in those receiving LA.
    3 context sentences
    Summary · context
    Multicenter, double-blind, double-dummy, randomized clinical trial.
    Summary · context
    Fifty-five women with moderate or severe pelvic pain and laparoscopically diagnosed endometriosis.
    Summary · context
    Six-month treatment with oral gestrinone (n = 27) or IM depot LA (n = 28) followed by 6-month follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.